Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK

• DOI: 10.2147/ceor.s135609
• Publication Date: 2017-10-16T22:20:12Z
• Authors: Michele Wilson; Ismail Azzabi Zouraq; Helene Chevrou-Se...; Ross Selby; Matthew C Kerrigan
• Keywords: Vedolizumab

Objective: To examine the clinical and economic impact of vedolizumab compared with conventional therapy in treatment moderately-to-severely active ulcerative colitis (UC) UK based on results GEMINI I trial. Methods: A decision-analytic model Microsoft Excel was used to compare (aminosalicylates, corticosteroids, immunomodulators) for patients UC UK. We considered following three populations: overall intent-to-treat population from trial, naïve anti-TNF therapy, those who had failed anti-TNF-therapy. Population characteristics efficacy data were obtained Other inputs (eg, unit costs, probability surgery, mortality) published literature. Time horizon a lifetime horizon, costs outcomes discounted by 3.5% per year. One-way probabilistic sensitivity analyses conducted measure parameter uncertainty. Results: Vedolizumab incremental cost-effectiveness ratios £4,095/quality-adjusted life-year (QALY), £4,423/QALY, £5,972/QALY intent-to-treat, anti-TNF-naïve, anti-TNF-failure populations, respectively. Patients accrued more QALYs while incurring than therapy. The showed that most sensitive induction response transition probabilities each treatment. Conclusion: suggest may be cost-effective option both anti-TNF-naïve UC. Keywords: colitis, cost-effectiveness, vedolizumab, inflammatory bowel disease